These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 25759103)

  • 21. Coronary artery bypass grafting vs percutaneous coronary intervention and long-term mortality and morbidity in multivessel disease: meta-analysis of randomized clinical trials of the arterial grafting and stenting era.
    Sipahi I; Akay MH; Dagdelen S; Blitz A; Alhan C
    JAMA Intern Med; 2014 Feb; 174(2):223-30. PubMed ID: 24296767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Implications and Debates on the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches Trial.
    Saito Y; Nishi T; Saito K; Kitahara H; Kawase Y; Matsuo H; Kobayashi Y
    Cardiol Rev; 2022 Sep-Oct 01; 30(5):234-240. PubMed ID: 33758121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes after complete versus incomplete revascularization of patients with multivessel coronary artery disease: a meta-analysis of 89,883 patients enrolled in randomized clinical trials and observational studies.
    Garcia S; Sandoval Y; Roukoz H; Adabag S; Canoniero M; Yannopoulos D; Brilakis ES
    J Am Coll Cardiol; 2013 Oct; 62(16):1421-31. PubMed ID: 23747787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conservative versus invasive stable ischemic heart disease management strategies: what do we plan to learn from the ISCHEMIA trial?
    Cheng-Torres KA; Desai KP; Sidhu MS; Maron DJ; Boden WE
    Future Cardiol; 2016 Jan; 12(1):35-44. PubMed ID: 26696561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials.
    Pursnani S; Korley F; Gopaul R; Kanade P; Chandra N; Shaw RE; Bangalore S
    Circ Cardiovasc Interv; 2012 Aug; 5(4):476-90. PubMed ID: 22872053
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strategies in stable ischemic heart disease: lessons from the COURAGE and BARI-2D trials.
    Fernandez SF; Boden WE
    Curr Atheroscler Rep; 2010 Nov; 12(6):423-31. PubMed ID: 20845088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.
    Shaw LJ; Berman DS; Maron DJ; Mancini GB; Hayes SW; Hartigan PM; Weintraub WS; O'Rourke RA; Dada M; Spertus JA; Chaitman BR; Friedman J; Slomka P; Heller GV; Germano G; Gosselin G; Berger P; Kostuk WJ; Schwartz RG; Knudtson M; Veledar E; Bates ER; McCallister B; Teo KK; Boden WE;
    Circulation; 2008 Mar; 117(10):1283-91. PubMed ID: 18268144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Percutaneous coronary intervention versus medical therapy in stable coronary artery disease: the unresolved conundrum.
    Epstein SE; Waksman R; Pichard AD; Kent KM; Panza JA
    JACC Cardiovasc Interv; 2013 Oct; 6(10):993-8. PubMed ID: 24156960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Percutaneous coronary interventions for stable ischemic heart disease in Italy.
    De Servi S; Olivari Z; Crimi G; Marino M; Alberti LP; Tagliabue E; Leonardi S
    J Cardiovasc Med (Hagerstown); 2019 Nov; 20(11):762-767. PubMed ID: 31361651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of impaired fractional flow reserve after coronary interventions on outcomes: a systematic review and meta-analysis.
    Wolfrum M; Fahrni G; de Maria GL; Knapp G; Curzen N; Kharbanda RK; Fröhlich GM; Banning AP
    BMC Cardiovasc Disord; 2016 Sep; 16(1):177. PubMed ID: 27608682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multivessel versus culprit lesion only percutaneous coronary intervention in cardiogenic shock complicating acute myocardial infarction: A systematic review and meta-analysis.
    de Waha S; Jobs A; Eitel I; Pöss J; Stiermaier T; Meyer-Saraei R; Fuernau G; Zeymer U; Desch S; Thiele H
    Eur Heart J Acute Cardiovasc Care; 2018 Feb; 7(1):28-37. PubMed ID: 28703046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Challenges with Evidence-Based Management of Stable Ischemic Heart Disease.
    Patel AV; Bangalore S
    Curr Cardiol Rep; 2017 Feb; 19(2):11. PubMed ID: 28185167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Role of Vascular Imaging in Guiding Routine Percutaneous Coronary Interventions: A Meta-Analysis of Bare Metal Stent and Drug-Eluting Stent Trials.
    Alsidawi S; Effat M; Rahman S; Abdallah M; Leesar M
    Cardiovasc Ther; 2015 Dec; 33(6):360-6. PubMed ID: 26363283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medical Therapy With Versus Without Revascularization in Stable Patients With Moderate and Severe Ischemia: The Case for Community Equipoise.
    Stone GW; Hochman JS; Williams DO; Boden WE; Ferguson TB; Harrington RA; Maron DJ
    J Am Coll Cardiol; 2016 Jan; 67(1):81-99. PubMed ID: 26616030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Revascularization strategies in patients with diabetes and stable ischemic heart disease: a systematic review and meta-analysis of randomized trials.
    Noguchi M; Ueyama H; Fujisaki T; Takagi H; Kuno T
    J Cardiovasc Med (Hagerstown); 2022 Apr; 23(4):242-246. PubMed ID: 35029867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison between patients included in randomized controlled trials of ischemic heart disease and real-world data. A nationwide study.
    Laursen PN; Holmvang L; Lønborg J; Køber L; Høfsten DE; Helqvist S; Clemmensen P; Kelbæk H; Jørgensen E; Lassen JF; Pedersen F; Høi-Hansen T; Therkelsen CJ; Tilsted HH; Jensen LO; Nepper-Christensen L; Sadjadieh G; Engstrøm T
    Am Heart J; 2018 Oct; 204():128-138. PubMed ID: 30103092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction.
    Pilgrim T; Vranckx P; Valgimigli M; Stefanini GG; Piccolo R; Rat J; Rothenbühler M; Stortecky S; Räber L; Blöchlinger S; Hunziker L; Silber S; Jüni P; Serruys PW; Windecker S
    Am Heart J; 2016 May; 175():56-65. PubMed ID: 27179724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PROTECTion against post-PCI microvascular dysfunction and post-PCI ischemia among antiplatelet and antithrombotic agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30).
    Gibson CM; Kirtane AJ; Morrow DA; Palabrica TM; Murphy SA; Stone PH; Scirica BM; Jennings LK; Herrmann HC; Cohen DJ; McCabe CH; Braunwald E;
    Am Heart J; 2006 Oct; 152(4):756-61. PubMed ID: 16996854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease.
    Hueb W; Lopes NH; Gersh BJ; Soares P; Machado LA; Jatene FB; Oliveira SA; Ramires JA
    Circulation; 2007 Mar; 115(9):1082-9. PubMed ID: 17339566
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.